CTI BioPharma Corp.'s (CTIC) Drug News Brings in Option Bulls

A positive development with a cancer drug sent bulls to CTI BioPharma Corp (CTIC)


Published on Feb 4, 2015 at 11:01 AM
Updated on Apr 20, 2015 at 5:09 PM

CTI BioPharma Corp (NASDAQ:CTIC) jumped 4.6% yesterday, closing at $2.29, after an independent data monitoring committee recommended continuing a clinical study of its ovarian cancer drug Opaxio. Options bulls ran with the news, picking up calls at three times the normal single-session rate.

Receiving the most action by far was the April 2 call, where it seems buy-to-open activity took place. These speculators are hoping for CTIC to extend its run above $2 through the close on Friday, April 17, when the options expire.

On the sentiment front, analysts are all-in on CTIC. All six covering brokerage firms rate the stock a "strong buy." Plus, the equity's average 12-month price target of $5.08 is more than double its current perch, and stands in territory not charted since May 2012.

Analysts have kept this positive outlook on CTI BioPharma Corp (NASDAQ:CTIC) despite its technical struggles. Since its mid-September high of $2.93, the security has lost 24.2%. At last check, CTIC was down 3.1% at $2.22.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

The Nevada Discovery That Could Jeopardize Chinese Dominance
Click to continue to advertiser's site.
Stocks Surge During Holiday-Shortened Week
Stocks chugged higher as the government responded to the coronavirus crisis with more funding
Bank Stocks Ease Investors Back Into Earnings Season
Bank stocks will kick off earnings season next week
The Top Lithium Play of 2020
Click to continue to advertiser's site.